Promising clinical activity of tepotinib plus osimertinib in NSCLC with MET amplification after progression on first-line osimertinib Presented ByProf. Julien Mazières, CHU de Toulouse, France TrialPhase 2, INSIGHT-2 ConferenceESMO 2022 16 November, 2022 18:10